Minoru Fujimori

This inventor holds 5 USPTO granted patents, plus 3 CIPO patents and 4 EPO patents. Top assignee: Anaeropharma Science, Inc.. Active years: 2010-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Minoru Fujimori. Retrieved from https://idiyas.com/inventor/minoru-fujimori

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5

% Patents Active = 60.0

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 4

Average Co-Inventor Count = 5.8

ph-index = 4

Forward Citations = 39(Granted Patents)

Location History:

Matsumoto, JP (2010 - 2014)
Ibaraki, JP (2012 - 2014)

Company Filing History:

5 out of 13

Anaeropharma Science, Inc.

patents

Years Active: 2010-2014

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8911721 - Method of constructing gene transport support (2014-12-16),

2. 8734779 - 5-fluorouracil-resistant bacteria and method for production thereof (2014-05-27),

3. 8338162 - Obligately anaerobic mutant lactic acid bacterium and preparation method therefor, and expression vector functioning in obligately anaerobic lactic acid bacterium (2012-12-25),

4. 8021653 - [object Object] (2011-09-20),

5. 7740835 - Anaerobic bacterium as a drug for cancer gene therapy (2010-06-22),

Title: Minoru Fujimori: Innovator in Gene Delivery Systems

Introduction

Minoru Fujimori is a prominent inventor based in Matsumoto, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of gene delivery systems. With a total of 5 patents, Fujimori's work focuses on innovative methods for constructing gene transport carriers that enhance therapeutic efficacy.

Latest Patents

Fujimori's latest patents include a method of constructing a gene transport support. This invention aims to provide an efficient method for creating a gene delivery carrier that exhibits favorable activity and expression efficiency of proteins introduced through transformation. Additionally, he has developed a pharmaceutical composition that includes a gene delivery carrier and a therapeutic agent for solid tumors, utilizing resistant bacteria. Another notable patent involves a method for producing a 5-fluorouracil-resistant microorganism that can grow in anaerobic tumor tissues and express cytosine deaminase, enhancing its antitumor activity.

Career Highlights

Minoru Fujimori is associated with Anaeropharma Science, Inc., where he continues to advance his research in gene therapy and microbial resistance. His innovative approaches have the potential to revolutionize cancer treatment by improving the delivery and effectiveness of therapeutic agents.

Collaborations

Fujimori has collaborated with notable colleagues such as Shun'ichiro Taniguchi and Jun Amano, contributing to the advancement of their shared research goals.

Conclusion

Minoru Fujimori's work in gene delivery systems exemplifies the intersection of innovation and biotechnology. His patents reflect a commitment to improving therapeutic strategies for cancer treatment, showcasing the importance of research in this critical field.

Profile summary based on public USPTO records.